[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-mellitus-in-obese\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-mellitus-in-obese":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,40,75,102,132,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100568534","beta-cell---liver-interactions-in-situations-of-modified-beta-cell-function-100568534",false,"NCT06682481","Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function","Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function: From Mice to Children","Inclusion Criteria:\n\n* Children aged 12 to 16 years\n* Obesity. Defined as a body-mass index above the 97th percentile.\n* Ability to give informed consent as documented by signature\n\nExclusion Criteria:\n\n* Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8.\n* Patients with known liver disease (other than NAFLD)\n* Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion.\n* Patients treated with a drug known to affect liver function","ALL","12 Years","16 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.",[25,26],"Obesity, Childhood","Type 2 Diabetes Mellitus in Obese","RECRUITING","2026-05-14",{"date":30,"type":31},"2026-05-18","ACTUAL",{"date":33,"type":31},"2024-11-22",{"date":35,"type":21},"2028-12-31",{"name":37,"class":38},"Philippe Klee, MD-PhD","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":63,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100460586","brain-health-in-youth-with-normal-weight-overweight-and-obesity-at-risk-for-type-2-diabetes-t2d-100460586","NCT05277558","Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)","Brain Health Across the Metabolic Continuum in Youth at Risk for Type 2 Diabetes (T2D)","Metabrain","Inclusion Criteria:\n\n* 12-17 yrs. old at visit 1, 12-19 yrs. old at visit 2, Tanner II or above (determined through an exam by a pediatric endocrinologist or certified nurse practitioner trained in pediatric endocrinology), otherwise healthy except for obesity, \\\u003C450 lbs. (due to MRI scanner limits), able and willing to lie flat within the MRI scanner and do cognitive testing, fluent in English.\n\nExclusion Criteria:\n\n* Syndromic obesity, history of bariatric surgery, insulin treatment (metformin allowed if \\\u003C 6 months) for T2D, contraindications for MRI (metal, claustrophobia), braces, pregnant (pregnancy test will be done on post-menarchal girls) or breastfeeding, inability to participate in cognitive testing due to sensory or language issues, intellectual disability, special education, pharmacologic treatment for Attention Deficit Hyperactivity Disorder (ADHD), prematurity (\\\u003C36 weeks gestation), complications at birth, neurologic co-morbidities (e.g., seizures, stroke, head injury with \\>10 min loss of consciousness), significant psychiatric disorders (e.g., schizophrenia, bipolar disorder, current major depression), taking psychoactive medications (e.g., antipsychotics) that would interfere with testing or reporting illegal drug use. Self-reported smoking and alcohol use and length of time with obesity will be assessed by history (although these measures may not be fully reliable).",true,"17 Years",{"count":51,"type":21},117,"Investigators propose to study youth across the spectrum of body mass index (BMI) and dysglycemia. This approach will allow investigators to disentangle the relationship of key features of type 2 diabetes (T2D) risk (e.g. obesity) with intermediary physiologic changes (e.g. insulin resistance, inflammation, β-cell dysfunction and dysglycemia) that pose a risk for the brain. Investigators will determine which of these factors are most associated with differences in brain structure and function among groups, over time, and how these effects differ from normal neurodevelopment.",[54,26,55,56,57,25,58,59,60,61,62],"Type2 Diabetes","Dysglycemia","Microvascular Complications","Brain Structure","Diabetes in Adolescence","Inflammation","Insulin Resistance","Overweight, Childhood","Cognitive Decline",[64],"Brain, Health, Youth, Type 2 Diabetes Mellitus, overweight, obesity","2025-12-16",{"date":67,"type":31},"2025-12-18",{"date":69,"type":31},"2022-05-24",{"date":71,"type":21},"2027-10-31",{"name":73,"class":38},"Washington University School of Medicine",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":48,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":39},"100503671","phase-4-pioglitazone-on-heart-failure-in-type-2-diabetes-mellitus-participants-100503671","NCT05838287","Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants","Pioglitazone, Lipotoxicity, and Heart Failure With Preserved Ejection Fraction (HFpEF)","PIOHF","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged 30-70 years\n4. Body Mass Index (BMI) of 27.5-40kg\u002Fm²\n5. HbA1c of 6.5 to 10%\n6. Blood pressure of less than or equal to 145\u002F65mmHg\n7. eGFR greater than 45 ml\u002Fmin\u002F1.73m²\n8. Subject must have HFpEF (EF \\> 50% by ECHO screening)\n9. NYHA class II-III heart failure\n10. Only T2D patients treated with diet\u002Fexercise, metformin, sulfonylurea, metformin\u002FSU, DPP4i or insulin will be studied.\n11. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional \\[4 weeks\\] after the end of study participation.\n12. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.\n\nExclusion Criteria:\n\n1. Subjects with history of osteoporosis or proliferative diabetic retinopathy\n2. Subjects with Heart failure due to restrictive or infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, severe valvular heart disease, etc. will be excluded\n3. Patients with symptomatic coronary artery disease.\n4. Subjects with significant change in diuretic management during the month prior to screening (defined by doubling of diuretic dose, or addition of another HF medication).\n5. Subjects treated with a GLP-1 RA or thiazolidinedione.\n6. Subjects treated with a SGLT2i\n7. Pregnancy or lactation\n8. Known allergic reactions to components of the study interventions.\n9. Any metal plates, parts, screws, shrapnel, pins in body, or cardiac (heart) pacemaker","30 Years","70 Years",{"count":86,"type":21},78,"INTERVENTIONAL",[89],"PHASE4","Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are:\n\n1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals.\n2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.",[26,92],"Heart Failure With Preserved Ejection Fraction","2025-08-26",{"date":95,"type":31},"2025-08-27",{"date":97,"type":31},"2023-07-10",{"date":99,"type":21},"2030-01",{"name":101,"class":38},"The University of Texas Health Science Center at San Antonio",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":48,"sex":16,"minAge":109,"maxAge":84,"enrollmentInfo":110,"targetDuration":4,"studyType":87,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100565563","implementation-of-a-peer-leader-facilitated-dyadic-intervention-100565563","NCT06643806","Implementation of a Peer Leader-facilitated Dyadic Intervention","Implementation of a Peer Leader-facilitated Dyadic Intervention to Decrease Cardiovascular Disease Risk Among First Generation Asian Indian Immigrants","Inclusion Criteria:\n\n* community-dwelling first generation Asian Indian (AI) immigrants (in marital dyads) between the ages of 18-70 years of age who can read and write English and are technology literate.\n\nExclusion Criteria:\n\n* AIs not in a marital dyad, those below the age of 20 or above 70 years or those born in the US or visiting the US from India.","20 Years",{"count":111,"type":21},80,[113],"NA","This Pilot Study Large Application builds upon the results of our prior work to 1) Implement and pilot test a peer leader-facilitated 12-week dyadic intervention (Community Health among Asian Indian immigrants (CHAI) Dyad study) using a cluster randomization design, to decrease CVD risk among first generation AI immigrants; and 2) Assess the feasibility\u002Facceptability of a full-scale intervention. Twenty marital dyads from the site randomly assigned as the intervention site will receive the 12- week peer leader-facilitated dyadic intervention, while 20 dyads from the site randomly assigned as the \"usual care\" control group site will receive a basic cardiovascular lifestyle modification program. Both groups will meet weekly (90 min. classes) for 12 weeks in a hybrid format (a combination of face to face and remote learning). The intervention is designed to address factors that we identified in our previous study as contributing to a syndemic of cardiovascular disease among AI immigrants including acculturation stress, family history and genetic risk, physical inactivity, as well as a high fat, high-carbohydrate, high-calorie diet.",[116,26,117],"Cardiovascular Diseases","Hyperlipidemias",[119,120,121],"Community based participatory research","Asian Indian immigrants","Acculturation stress","NOT_YET_RECRUITING","2024-10-15",{"date":125,"type":31},"2024-10-16",{"date":127,"type":21},"2025-02",{"date":129,"type":21},"2025-07",{"name":131,"class":38},"Rutgers, The State University of New Jersey",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":87,"phases":143,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":74},"100554323","lifestyle-intervention-to-reduce-the-risk-of-sarcopenia-in-adults-with-diabetes--obesity-treated-with-semaglutide-100554323","NCT06497595","Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide","Exercise and Nutritional Intervention to Reduce the Risk of Sarcopenia in Older Adults With Type 2 Diabetes and Obesity Treated With Semaglutide: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients 65-75 years old.\n2. Patients who were previously diagnosed with type 2 diabetes.\n3. Overweight \u002F obesity (body mass index, BMI ≥ 27 kg\u002Fm2).\n\nExclusion Criteria:\n\n1. Patients with significant hearing or visual disability.\n2. Patients with Estimated Glomerular Filtration Rate (eGFR)\\\u003C30 ml\u002Fmin\u002F1.73 m2.\n3. Patients who are in active nutritional therapy.\n4. Patients who changed their diet recently (\\\u003C 1 month) and\u002For in a weight-loss program with \\>5% weight loss or used anti-obesity drugs in the last 3 months.\n5. Patients who reported a weight loss of \\>5kg within 90 days of screening\n6. Patients who were on Glucagon-like peptide-1 receptor agonists (GLP-1-RA) treatment during the last 3 months.\n7. Patients with musculoskeletal disorders, which, by the judgment of the investigators, would limit their ability to perform the exercise training.\n8. Patients with neurological diseases, which by the judgment of the investigators, would affect their ability to participate in the trial.\n9. Patients with a history of amputation that impairs their ability to participate in the exercise program.\n10. Patients with disabilities, which, by the judgment of the investigators, would affect their ability to participate in the trial.\n11. Patients who use a walking aid.\n12. Patients who are currently using systemic steroids.\n13. Patients with active oncological diseases, excluding non-melanoma skin cancer.\n14. Patients with diagnosed dementia or cognitive impairment that, in the view of the researchers, may impair their ability to sign a consent form or participate in the trial.\n15. Patients who were hospitalized in the past month.\n16. Patients who exercise regularly and in the eyes of the examiner will not benefit from the intervention program.\n17. Anyone who is not suitable to participate in the study, according to the researcher's discretion.\n18. Any contraindication to Magnetic resonance imaging (MRI) (e.g., MRI non-compatible cardiac implantable electronic device, metallic foreign bodies, implantable neurostimulation system, cochlear implants\u002Fear implant, non-removable drug infusion pumps, catheters with metallic components, cerebral artery aneurysm clips which), or inability to perform an MRI scanner (e.g., claustrophobia).\n19. Patients who do not fit within the measurement field of view of the Dual-energy X-ray absorptiometry (DXA) scanner in a supine position with the arms next to the body.","65 Years","75 Years",{"count":142,"type":21},60,[113],"This study aims to test whether a multi-disciplinary intervention involving exercise and nutrition can slow down the decline in physical function, muscle strength and mass in older adults (aged 65-75) with Type 2 diabetes (T2D) and obesity treated with Semaglutide.\n\nThe main questions it aims to answer are:\n\nIn older people with T2D and obesity, treated with Semaglutide, does a multi-disciplinary intervention of exercise and nutrition compared to standard health recommendations:\n\n1. Reduce the rate of decline in muscle mass?\n2. Reduce the rate of decline in muscle strength?\n3. Reduce the rate of decline in physical function?\n\nParticipants will:\n\nAdminister Semaglutide once weekly for 6 months. Visit the clinic once every 8 weeks for checkups and tests. Keep a diary of their exercise and food consumption. Participants in the intervention group will participate in an online exercise program and will receive personal nutritional counseling.",[26],[147,148,149,150,151,152,153],"older adults","sarcopenia","obesity","type 2 diabetes","semaglutide","exercise","physical capacity","2024-08-20",{"date":156,"type":31},"2024-08-22",{"date":158,"type":21},"2024-08-30",{"date":160,"type":21},"2025-08-30",{"name":162,"class":163},"Sheba Medical Center","OTHER_GOV",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":87,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":39},"100550060","lcmd-for-type-2-diabetes-remission-evaluation-of-effectiveness-and-exploration-of-individual-differences-100550060","NCT06442150","LCMD for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences","Low-Calorie Medicinal Diet for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences","LCMD","Inclusion Criteria:\n\n* Physician-diagnosed T2DM\n* The history of T2DM less than 6 years\n* Most recent HbA1c higher than 6.5%\n* Body mass index: 24-45 kg\u002Fm2\n* Fasting C-p ≥1.1 ng\u002Fml\n* Inability to provide informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes, type 2 diabetes currently treated with insulin, or HbA1c ≥12%\n* Cardiovascular events within 6 months before trial\n* Current use of anti-obesity medications, eating disorders, dieting behaviors, or weight loss \\>5 kg within 6 months before trial\n* Chronic kidney disease stage 3b or above (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n* Any condition causing fluid overload, such as heart failure or liver cirrhosis\n* Previously diagnosed psychiatric disorders (e.g., schizophrenia, post-traumatic stress disorder, obsessive-compulsive disorder), uncontrolled depression, or epilepsy\n* Severe arthritis or active gout\n* Active gallstone disease or known as asymptomatic gallstones\n* Concurrent enrollment in another clinical trial\n* Pregnancy, lactation, or planned conception during the study\n* Substance abuse\n* Known malignancy\n* Comorbidities increasing dietary intervention risk (e.g., biliary disorders)\n* Long-term use of antibiotics, corticosteroids, NSAIDs, or PPIs\n* Chronic gastrointestinal disorders affecting gut microbiota (e.g., ulcerative colitis)\n* Severe hepatic impairment (ALT \\>2.5× ULN)\n* Inability to provide informed consent","18 Years","60 Years",{"count":175,"type":21},170,[113],"Type 2 diabetes (T2DM) has become a major public health problem. Achieving remission (HbA1c\\\u003C6.5% without glucose-lowering medications) has recently become a new treatment goal. Low-calorie diets effectively induce remission, but adverse effects like fatigue, appetite, and constipation hinder success. Integrating traditional Chinese medicine (TCM) herbs into a low-calorie diet may alleviate adverse effects and improve remission rates.\n\nThis project investigates the efficacy of a Low-Calorie Medicine Diet (LCMD) in achieving T2DM remission among overweight\u002Fobese individuals through a randomized controlled trial. The investigators will explore individual differences in remission and elucidate the underlying biological mechanisms, focusing on the brain-gut-microbiota axis. By integrating nutrition and TCM dietetics, this project provides a novel, evidence-based approach to managing T2DM in Chinese populations.",[26,179],"Type 2 Diabetes",[181,182,183,184],"Remission of type 2 diabetes","Low Calorie Diet","Medicined Diet","Brain-Gut-Microbiome axis","2024-05-29",{"date":187,"type":31},"2024-06-04",{"date":189,"type":21},"2024-06-01",{"date":191,"type":21},"2027-11-30",{"name":193,"class":38},"Shanghai Municipal Hospital of Traditional Chinese Medicine"]